Publications by authors named "G A Huls"
Background: High dose chemotherapy and autologous stem cell transplantation (HDT/ASCT) remains the preferred first line consolidation strategy for newly diagnosed multiple myeloma (MM). However, The role of HDT/ASCT in first relapse is uncertain in the context of novel therapies. This study evaluates real-world outcomes of MM patients in first relapse, focusing on the role of consolidative HDT/ASCT.
View Article and Find Full Text PDFIn pediatric hematopoietic cell transplantation (HCT) recipients, transplanted donor cells may need to function far beyond normal human lifespan. Here, we investigated the risk of clonal hematopoiesis (CH) in 144 pediatric long-term HCT survivors and 258 non-transplanted controls. CH was detected in 16% of HCT recipients and 8% of controls, at variant allele frequencies (VAFs) of 0.
View Article and Find Full Text PDFAcute myeloid leukemia (AML) is a heterogeneous hematologic malignancy characterized by the (oligo)clonal expansion of myeloid progenitor cells. Despite advances in treatment, AML remains challenging to cure, particularly in patients with specific genetic abnormalities. Menin inhibitors have emerged as a promising therapeutic approach, targeting key genetic drivers of AML such as KMT2A rearrangements and NPM1 mutations.
View Article and Find Full Text PDFArticle Synopsis
- Acute myeloid leukemia (AML) is difficult to treat due to its genetic diversity, protective tumor microenvironment, and immune evasion, making the search for effective therapies critical.
- The inhibitor JNJ-75276617 (bleximenib) targets the menin-KMT2A interaction, showing promise in preclinical studies by impairing cell growth and promoting differentiation in AML cells, particularly in specific genetic subtypes.
- Treatment with JNJ-75276617 leads to epigenetic changes that enhance the expression of MHC class I and II, which could improve the effectiveness of T cell-mediated therapies against leukemia.
Introduction: Enteropathy-associated T-cell lymphoma (EATL) is a peripheral T-cell lymphoma (PTCL) with a poor prognosis. Cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) with or without etoposide consolidated by autologous stem cell transplantation (ASCT) are recommended for fit PTCL patients. The role of etoposide and ASCT in EATL is unclear.
View Article and Find Full Text PDF